COAG Financials

Income Statement
MetricQ2 2026
Revenue
0
Cost of Revenue
0
Gross Profit
0
Operating Expenses
26.1M
R&D
20.3M
SG&A
5.7M
Operating Income
-26079000
EBITDA
-26004000
Net Income
-24150000
EPS (Basic)
$-0.80
EPS (Diluted)
$-0.80
Shares (Diluted)
30.1M
MarketsMoversWatchlist
Hemab Therapeutics (COAG) — Financials